Симуляция графика K-линий, фактические данные указаны на торговой странице
Ключевые данные
Открытие вчера
$0.60
Пред. закрытие
$0.74
Вчерашний диапазон
$0.60 - $0.75
Диапазон 52 нед.
$0.53 - $2.55
Объем торговли
20.522M
МС
$204.154M
P/E
--
EPS
$-0.66
Обзор компании
NASDAQ
Humacyte Inc (HUMA) is a pioneering biotechnology company specializing in vascular and regenerative medicine, with a focus on the development of human acellular vessels (HAVs). These innovative off-the-shelf products address critical needs in vascular reconstruction and chronic disease management, enhancing patient outcomes while potentially lowering healthcare costs. Utilizing its advanced technology platform, Humacyte is strategically positioned to lead advancements in transplantation and tissue engineering, solidifying its role as a transformative force in the evolving medical therapies landscape.
СекторHEALTHCARE
ОтрасльBIOTECHNOLOGY
Штаб-квартира2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM, NC, UNITED STATES, 27713
Владение базовыми токенизированными активами с привязкой 1:1 к акциям США. Подходит для долгосрочного стоимостного инвестирования с возможностью получения дивидендов (при их наличии).
Характер инвестиций:Владение базовыми токенизированными активами с привязкой 1:1 к акциям США; цена колеблется синхронно с оригинальными акциями на Nasdaq.
Право на дивиденды:Согласно политике компании. При выплате дивидендов по базовым акциям платформа распределяет эквивалентные дивиденды в USDT пропорционально объему владения.
Кому подходит:Долгосрочные и стоимостные инвесторы, которые верят в успех компании в долгосрочной перспективе и хотят получать дивидендную доходность.
Риски:Риск волатильности цен на акции, основной капитал может подвергнуться убыткам, долгосрочное владение требует учета циклических колебаний рынка.
Правила торговли:Расчеты в USDT, торговля 24/7, без минимального порога депозита, один аккаунт для спота и фьючерсов.
HUMA operates in the healthcare sector, specializing in innovative solutions for medical research and patient care technologies. The company’s core business includes developing advanced tools to improve health outcomes and streamline clinical studies. HUMA focuses on leveraging technology to address gaps in healthcare delivery, making it a key player in its industry.
HUMA is part of the healthcare technology industry, which combines medical advancements with digital tools. Its competitors typically include companies specializing in similar segments, such as digital health platforms and AI-based clinical research solutions. Rival companies may vary depending on specific areas of focus within the industry.
HUMA generates revenue through its healthcare technologies and services that enhance medical research and patient outcomes. Key drivers include ongoing adoption of technological solutions across healthcare providers, partnerships with clinical institutions, and scaling its efforts in research-led healthcare initiatives.
HUMA currently does not pay dividends, as many healthcare technology companies reinvest earnings into research, development, and expansion. Investors should consider whether the company’s growth-focused strategy aligns with their portfolio goals before investing.
HUMA presents opportunities for investors due to its focus on healthcare technology, which is a growing and evolving sector. The company’s innovative approaches to medical research and improving patient care could offer long-term growth potential. However, risks include market competition and the need for consistent funding to support expansion.
Investors should weigh risks such as potential competition from other healthcare technology companies, regulatory challenges in the industry, and dependence on market adoption of its innovations. Additionally, scalability and continued investment in development remain critical factors for the company’s success.
HUMA’s valuation within the healthcare technology industry depends on factors like revenue growth, profitability, and market positioning. Investors can compare its key metrics, such as price-to-earnings or price-to-sales ratios, with industry peers to determine its relative value and potential.
HUMA positions itself for growth by focusing on technological innovation, strategic partnerships, and addressing unmet needs in healthcare delivery. The company’s commitment to advancing patient outcomes and enhancing medical research processes serves as a foundation for long-term growth opportunities.
Предупреждение о рисках
1.Цены на акции могут сильно колебаться, инвестируйте осторожно. Прошлые результаты не гарантируют будущую доходность.
2.Торговля цифровыми активами сопряжена с рыночными, техническими и иными рисками. Пожалуйста, принимайте взвешенные решения и рационально распределяйте активы.
3.Информация на этой странице предназначена только для ознакомления и не является инвестиционной рекомендацией.
